18F-FDG PET/CT and PET/MRI perform equally well in cancer patients: Evidence from studies in more than 2300 patients

(18)F-FDG-PET/CT has become the reference standard in oncologic imaging against which the performance of other imaging modalities is measured. The promise of PET/MRI includes multi-parametric imaging to further improve diagnosis and phenotyping of cancer.

Rather than focusing on these capabilities many investigators have however examined whether (18)F-FDG-PET combined with mostly anatomic MRI improves cancer staging and restaging. Following a description of PET/MRI designs, and a discussion of technical and operational issues we review the available literature to determine whether cancer assessments are improved with PET/MRI. The available data show that PET/MRI is feasible and performs equally well as PET/CT in most cancers. Diagnostic advantages may be achievable in prostate cancer and in bone metastases while disadvantages may exist in lung nodule assessments. We conclude that (18)F-FDG PET/MRI and PET/CT provide comparable diagnostic information when MRI is simply used to provide the anatomical framework. Thus, PET/MRI could be used in lieu of PET/CT if this approach becomes economically viable and if reasonable workflows can be established. Future studies should explore the multi-parametric potential of MRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Jan 07 [Epub ahead of print]

Claudio Spick, Ken Herrmann, Johannes Czernin

UCLA School of Medicine, United States. , UCLA School of Medicine, United States. , UCLA School of Medicine, United States.



Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.